カテゴリ： QYResearch, 世界, 医療/バイオ

核酸医薬品の世界市場2025年：アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他

■ 英語タイトル：Global Nucleic Acid Drugs Market Research Report 2025

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8552）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8552
■ 発行日：2025年3月
■ 調査対象地域：グローバル
■ 産業分野：新技術
■ ページ数：85
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥417,600見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥626,400見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥835,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[核酸医薬品の世界市場2025年：アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は核酸医薬品のグローバル市場について調査・分析し、世界の核酸医薬品市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他）、用途別セグメント分析（遺伝病、がん、循環器疾患、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Sarepta Therapeutics、Ionis Pharmaceuticals、Alnylam、Mina Therapeutics、BioNTech、NeXstar Pharmaceuticals、Nippon Shinyaku、Moderna Therapeutics、CureVac、Regulus Therapeutics、Miragen Therapeuticsなどが含まれています。核酸医薬品のグローバル市場は、2024年にXXX米ドル、2031年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。貿易戦争とロシア・ウクライナ戦争の影響は、核酸医薬品市場規模を算出する際に考慮しました。

・核酸医薬品市場の概要
- 核酸医薬品の種類別セグメント
- 世界の核酸医薬品市場規模：タイプ別分析（アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他）
- 核酸医薬品の用途別セグメント
- 世界の核酸医薬品市場規模：用途別分析（遺伝病、がん、循環器疾患、その他）
- 世界の核酸医薬品市場規模予測（2020年-2031年）

・核酸医薬品市場の成長トレンド
- 核酸医薬品の地域別市場規模（2020年-2031年）
- 核酸医薬品市場ダイナミクス
- 核酸医薬品の業界動向
- 核酸医薬品市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他
- 世界の核酸医薬品のタイプ別市場規模（2020年-2025年）
- 世界の核酸医薬品のタイプ別市場規模（2024年-2029年）

・用途別セグメント：遺伝病、がん、循環器疾患、その他
- 世界の核酸医薬品の用途別市場規模（2020年-2025年）
- 世界の核酸医薬品の用途別市場規模（2024年-2029年）

・核酸医薬品の地域別市場規模
- 北米の核酸医薬品市場規模（2020年-2031年）
- 米国の核酸医薬品市場規模（2020年-2031年）
- ヨーロッパの核酸医薬品市場規模（2020年-2031年）
- アジア太平洋の核酸医薬品市場規模（2020年-2031年）
- 中国の核酸医薬品市場規模（2020年-2031年）
- 日本の核酸医薬品市場規模（2020年-2031年）
- 韓国の核酸医薬品市場規模（2020年-2031年）
- インドの核酸医薬品市場規模（2020年-2031年）
- オーストラリアの核酸医薬品市場規模（2020年-2031年）
- 中南米の核酸医薬品市場規模（2020年-2031年）
- 中東・アフリカの核酸医薬品市場規模（2020年-2031年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Sarepta Therapeutics、Ionis Pharmaceuticals、Alnylam、Mina Therapeutics、BioNTech、NeXstar Pharmaceuticals、Nippon Shinyaku、Moderna Therapeutics、CureVac、Regulus Therapeutics、Miragen Therapeutics

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Nucleic Acid Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of % during the forecast period 2025-2031. The influence of trade war and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nucleic Acid Drugs is estimated to increase from $ million in 2023 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleic Acid Drugs is estimated to increase from $ million in 2023 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Nucleic Acid Drugs in Genetic Disease is estimated to increase from $ million in 2023 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The key global companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Mina Therapeutics, BioNTech, NeXstar Pharmaceuticals, Nippon Shinyaku, Moderna Therapeutics and CureVac, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Drugs.
The Nucleic Acid Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acid Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics
Segment by Type
Antisense Nucleic Acid Drugs
siRNA Drugs
saRNA Drugs
miRNA Drugs
mRNA Drugs
other
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antisense Nucleic Acid Drugs
1.2.3 siRNA Drugs
1.2.4 saRNA Drugs
1.2.5 miRNA Drugs
1.2.6 mRNA Drugs
1.2.7 other
1.3 Market by Application
1.3.1 Global Nucleic Acid Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Drugs Market Perspective (2020-2031)
2.2 Nucleic Acid Drugs Growth Trends by Region
2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Nucleic Acid Drugs Historic Market Size by Region (2020-2025)
2.2.3 Nucleic Acid Drugs Forecasted Market Size by Region (2026-2031)
2.3 Nucleic Acid Drugs Market Dynamics
2.3.1 Nucleic Acid Drugs Industry Trends
2.3.2 Nucleic Acid Drugs Market Drivers
2.3.3 Nucleic Acid Drugs Market Challenges
2.3.4 Nucleic Acid Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Drugs Players by Revenue
3.1.1 Global Top Nucleic Acid Drugs Players by Revenue (2020-2025)
3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid Drugs Revenue
3.4 Global Nucleic Acid Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2022
3.5 Nucleic Acid Drugs Key Players Head office and Area Served
3.6 Key Players Nucleic Acid Drugs Product Solution and Service
3.7 Date of Enter into Nucleic Acid Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Drugs Breakdown Data by Type
4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2020-2025)
4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2026-2031)
5 Nucleic Acid Drugs Breakdown Data by Application
5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2020-2025)
5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Nucleic Acid Drugs Market Size (2020-2031)
6.2 North America Nucleic Acid Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Nucleic Acid Drugs Market Size by Country (2020-2025)
6.4 North America Nucleic Acid Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Drugs Market Size (2020-2031)
7.2 Europe Nucleic Acid Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Nucleic Acid Drugs Market Size by Country (2020-2025)
7.4 Europe Nucleic Acid Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Drugs Market Size (2020-2031)
8.2 Asia-Pacific Nucleic Acid Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Drugs Market Size (2020-2031)
9.2 Latin America Nucleic Acid Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Nucleic Acid Drugs Market Size by Country (2020-2025)
9.4 Latin America Nucleic Acid Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Drugs Market Size (2020-2031)
10.2 Middle East & Africa Nucleic Acid Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Detail
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Detail
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Detail
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid Drugs Introduction
11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2020-2025)
11.3.5 Alnylam Recent Development
11.4 Mina Therapeutics
11.4.1 Mina Therapeutics Company Detail
11.4.2 Mina Therapeutics Business Overview
11.4.3 Mina Therapeutics Nucleic Acid Drugs Introduction
11.4.4 Mina Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
11.4.5 Mina Therapeutics Recent Development
11.5 BioNTech
11.5.1 BioNTech Company Detail
11.5.2 BioNTech Business Overview
11.5.3 BioNTech Nucleic Acid Drugs Introduction
11.5.4 BioNTech Revenue in Nucleic Acid Drugs Business (2020-2025)
11.5.5 BioNTech Recent Development
11.6 NeXstar Pharmaceuticals
11.6.1 NeXstar Pharmaceuticals Company Detail
11.6.2 NeXstar Pharmaceuticals Business Overview
11.6.3 NeXstar Pharmaceuticals Nucleic Acid Drugs Introduction
11.6.4 NeXstar Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025)
11.6.5 NeXstar Pharmaceuticals Recent Development
11.7 Nippon Shinyaku
11.7.1 Nippon Shinyaku Company Detail
11.7.2 Nippon Shinyaku Business Overview
11.7.3 Nippon Shinyaku Nucleic Acid Drugs Introduction
11.7.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2020-2025)
11.7.5 Nippon Shinyaku Recent Development
11.8 Moderna Therapeutics
11.8.1 Moderna Therapeutics Company Detail
11.8.2 Moderna Therapeutics Business Overview
11.8.3 Moderna Therapeutics Nucleic Acid Drugs Introduction
11.8.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
11.8.5 Moderna Therapeutics Recent Development
11.9 CureVac
11.9.1 CureVac Company Detail
11.9.2 CureVac Business Overview
11.9.3 CureVac Nucleic Acid Drugs Introduction
11.9.4 CureVac Revenue in Nucleic Acid Drugs Business (2020-2025)
11.9.5 CureVac Recent Development
11.10 Regulus Therapeutics
11.10.1 Regulus Therapeutics Company Detail
11.10.2 Regulus Therapeutics Business Overview
11.10.3 Regulus Therapeutics Nucleic Acid Drugs Introduction
11.10.4 Regulus Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
11.10.5 Regulus Therapeutics Recent Development
11.11 Miragen Therapeutics
11.11.1 Miragen Therapeutics Company Detail
11.11.2 Miragen Therapeutics Business Overview
11.11.3 Miragen Therapeutics Nucleic Acid Drugs Introduction
11.11.4 Miragen Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
11.11.5 Miragen Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Nucleic Acid Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antisense Nucleic Acid Drugs
Table 3. Key Players of siRNA Drugs
Table 4. Key Players of saRNA Drugs
Table 5. Key Players of miRNA Drugs
Table 6. Key Players of mRNA Drugs
Table 7. Key Players of other
Table 8. Global Nucleic Acid Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Nucleic Acid Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Nucleic Acid Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Nucleic Acid Drugs Market Share by Region (2020-2025)
Table 12. Global Nucleic Acid Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Nucleic Acid Drugs Market Share by Region (2026-2031)
Table 14. Nucleic Acid Drugs Market Trends
Table 15. Nucleic Acid Drugs Market Drivers
Table 16. Nucleic Acid Drugs Market Challenges
Table 17. Nucleic Acid Drugs Market Restraints
Table 18. Global Nucleic Acid Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Nucleic Acid Drugs Market Share by Players (2020-2025)
Table 20. Global Top Nucleic Acid Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2022)
Table 21. Ranking of Global Top Nucleic Acid Drugs Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Nucleic Acid Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Nucleic Acid Drugs Product Solution and Service
Table 25. Date of Enter into Nucleic Acid Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Nucleic Acid Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Nucleic Acid Drugs Revenue Market Share by Type (2020-2025)
Table 29. Global Nucleic Acid Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Nucleic Acid Drugs Revenue Market Share by Type (2026-2031)
Table 31. Global Nucleic Acid Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Nucleic Acid Drugs Revenue Market Share by Application (2020-2025)
Table 33. Global Nucleic Acid Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Nucleic Acid Drugs Revenue Market Share by Application (2026-2031)
Table 35. North America Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Nucleic Acid Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Nucleic Acid Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Nucleic Acid Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Nucleic Acid Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Nucleic Acid Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Nucleic Acid Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Nucleic Acid Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Nucleic Acid Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Nucleic Acid Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Nucleic Acid Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Nucleic Acid Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 50. Sarepta Therapeutics Company Detail
Table 51. Sarepta Therapeutics Business Overview
Table 52. Sarepta Therapeutics Nucleic Acid Drugs Product
Table 53. Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 54. Sarepta Therapeutics Recent Development
Table 55. Ionis Pharmaceuticals Company Detail
Table 56. Ionis Pharmaceuticals Business Overview
Table 57. Ionis Pharmaceuticals Nucleic Acid Drugs Product
Table 58. Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 59. Ionis Pharmaceuticals Recent Development
Table 60. Alnylam Company Detail
Table 61. Alnylam Business Overview
Table 62. Alnylam Nucleic Acid Drugs Product
Table 63. Alnylam Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 64. Alnylam Recent Development
Table 65. Mina Therapeutics Company Detail
Table 66. Mina Therapeutics Business Overview
Table 67. Mina Therapeutics Nucleic Acid Drugs Product
Table 68. Mina Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 69. Mina Therapeutics Recent Development
Table 70. BioNTech Company Detail
Table 71. BioNTech Business Overview
Table 72. BioNTech Nucleic Acid Drugs Product
Table 73. BioNTech Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 74. BioNTech Recent Development
Table 75. NeXstar Pharmaceuticals Company Detail
Table 76. NeXstar Pharmaceuticals Business Overview
Table 77. NeXstar Pharmaceuticals Nucleic Acid Drugs Product
Table 78. NeXstar Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 79. NeXstar Pharmaceuticals Recent Development
Table 80. Nippon Shinyaku Company Detail
Table 81. Nippon Shinyaku Business Overview
Table 82. Nippon Shinyaku Nucleic Acid Drugs Product
Table 83. Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 84. Nippon Shinyaku Recent Development
Table 85. Moderna Therapeutics Company Detail
Table 86. Moderna Therapeutics Business Overview
Table 87. Moderna Therapeutics Nucleic Acid Drugs Product
Table 88. Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 89. Moderna Therapeutics Recent Development
Table 90. CureVac Company Detail
Table 91. CureVac Business Overview
Table 92. CureVac Nucleic Acid Drugs Product
Table 93. CureVac Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 94. CureVac Recent Development
Table 95. Regulus Therapeutics Company Detail
Table 96. Regulus Therapeutics Business Overview
Table 97. Regulus Therapeutics Nucleic Acid Drugs Product
Table 98. Regulus Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 99. Regulus Therapeutics Recent Development
Table 100. Miragen Therapeutics Company Detail
Table 101. Miragen Therapeutics Business Overview
Table 102. Miragen Therapeutics Nucleic Acid Drugs Product
Table 103. Miragen Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) & (US$ Million)
Table 104. Miragen Therapeutics Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nucleic Acid Drugs Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 2. Global Nucleic Acid Drugs Market Share by Type: 2022 VS 2029
Figure 3. Antisense Nucleic Acid Drugs Features
Figure 4. siRNA Drugs Features
Figure 5. saRNA Drugs Features
Figure 6. miRNA Drugs Features
Figure 7. mRNA Drugs Features
Figure 8. other Features
Figure 9. Global Nucleic Acid Drugs Market Size Comparison by Application (2025-2031) & (US$ Million)
Figure 10. Global Nucleic Acid Drugs Market Share by Application: 2022 VS 2029
Figure 11. Genetic Disease Case Studies
Figure 12. Cancer Case Studies
Figure 13. Cardiovascular Diseases Case Studies
Figure 14. Other Case Studies
Figure 15. Nucleic Acid Drugs Report Years Considered
Figure 16. Global Nucleic Acid Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Nucleic Acid Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Nucleic Acid Drugs Market Share by Region: 2022 VS 2029
Figure 19. Global Nucleic Acid Drugs Market Share by Players in 2024
Figure 20. Global Top Nucleic Acid Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Nucleic Acid Drugs Revenue in 2024
Figure 22. North America Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Nucleic Acid Drugs Market Share by Country (2020-2031)
Figure 24. United States Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Nucleic Acid Drugs Market Share by Country (2020-2031)
Figure 28. Germany Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Nucleic Acid Drugs Market Share by Region (2020-2031)
Figure 36. China Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Nucleic Acid Drugs Market Share by Country (2020-2031)
Figure 44. Mexico Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Nucleic Acid Drugs Market Share by Country (2020-2031)
Figure 48. Turkey Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Nucleic Acid Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 51. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 52. Alnylam Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 53. Mina Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 54. BioNTech Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 55. NeXstar Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 56. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 57. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 58. CureVac Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 59. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 60. Miragen Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed

※参考情報

核酸医薬品とは、遺伝情報を担う核酸（DNAやRNA）を利用した医薬品のことを指します。この種の医薬品は、特定の遺伝子やその産物に対して標的を絞った治療が可能であり、従来の医薬品とは異なる新しい治療アプローチを提供します。近年、核酸医薬品の研究が急速に進められている背景には、遺伝子治療やRNA干渉（RNAi）技術の発展があると言えます。

核酸医薬品の特徴の一つは、その特異性です。従来の化学合成医薬品は、しばしば副作用が大きく、効き目が限られるという問題があります。一方、核酸医薬品は、特定の遺伝子や細胞に対して選択的に作用するため、よりターゲットを絞った治療が可能です。また、核酸は生体内で比較的安定した分子であり、一定の条件下では長時間作用することも特徴です。このため、治療効果を持続させやすいという利点があります。

核酸医薬品の種類には主に、抗センスオリゴヌクレオチド、siRNA（小干渉RNA）、mRNA（メッセンジャーRNA）、CRISPR（クリスパー）技術を用いた遺伝子編集などがあります。それぞれの方法は異なるメカニズムで作用しますが、共通して特定の遺伝子の発現を調節することを目的としています。

抗センスオリゴヌクレオチドは、標的とするmRNAの配列に相補的な短いDNAまたはRNA鎖であり、その結合を通じてmRNAの分解を促進します。これにより、特定のタンパク質の生成を抑えることが可能です。例えば、特定の遺伝子が病気を引き起こしている場合、その遺伝子の発現を抑制することで病気の進行を遅らせたり、改善したりする効果が期待されます。

siRNAは、細胞内に入るとRNAi（RNA干渉）というプロセスを介して特定のmRNAを切断し、タンパク質の合成をブロックします。この技術も特異的な治療が可能であり、がんやウイルス感染症の治療などで注目されています。siRNAを用いた研究は進行中で、いくつかの治療法が臨床試験段階にあります。

mRNAは、遺伝子情報を細胞内に伝える役割を果たす分子で、新しいタイプのワクチンや遺伝子治療に利用されています。特に、COVID-19のワクチンに使用されたmRNA技術は、迅速に効果的なワクチンを開発する上で重要な進展でした。この技術では、特定の抗原を作り出すためのmRNAが細胞内で翻訳され、免疫応答を引き起こします。

CRISPR技術は、特定の遺伝子を編集する能力を持つ強力なツールです。この技術を用いることで、特定の遺伝子を破壊したり、追加したりすることが可能で、遺伝子疾患の治療に広く応用が期待されています。CRISPRの利点は、その精度と効率にあり、これにより従来の遺伝子治療の限界を克服するパートナーとなり得ます。

核酸医薬品の用途は多岐にわたります。主な用途の一つは、がん治療です。がん細胞はしばしば異常な遺伝子発現を示し、これを標的にした治療が考案されています。また、遺伝子疾患、特に遺伝性の病気に対する治療法としても高い注目を集めており、特定の遺伝子の機能を補うことで症状を改善するアプローチが模索されています。

さらに、自免疫疾患や感染症、心血管疾患、神経疾患など、さまざまな病気に対する治療法開発も進められています。例えば、ウイルス感染の治療においては、特定のウイルスRNAを標的としたsiRNA療法が有望視されています。

核酸医薬品の開発には、関連技術が不可欠です。例えば、ナノキャリアやリポソームなど、核酸医薬品を細胞内に効果的に届けるためのデリバリーシステムが研究されています。これにより、核酸医薬品が体内で安定に存在し、薬効を発揮するための条件が整えられます。

また、合成技術の向上も重要な要素です。オリゴヌクレオチドの合成技術の進展により、より短期間で高品質の医薬品が得られるようになりました。さらに、生体内での安定性を向上させるための化学修飾も行われ、治療効果を向上させる取り組みが進んでいます。

総じて、核酸医薬品は従来の医薬品とは異なる新しい治療の選択肢を提供し、個々の患者の遺伝的背景に応じたパーソナライズド医療の実現に貢献する可能性があります。今後も研究が進むことで、さらなる治療法の開発が期待され、医療の未来を切り拓く重要な役割を果たすことが期待されています。核酸医薬品は、医療の進化を象徴する存在として、ますますその重要性を増していくことでしょう。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 細胞分析用イメージベースサイトメトリーの世界市場2023～2031：エンドユーザー別、治療領域別、作業場所別、地域別
  • 細胞分析の世界市場2023～2031：エンドユーザー別、治療領域別、技術別、作業場所別、国/地域別
  • 核酸治療薬CDMOのグローバル市場（2023～2030）：プロセス開発・最適化、製造サービス
  • うつ病治療薬の世界市場2025年：SSRI、SNRI、その他
  • 移動式ル自動核酸抽出/増幅装置の世界市場2025年：32T以下、96T
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8552 )"核酸医薬品の世界市場2025年：アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他" (英文：Global Nucleic Acid Drugs Market Research Report 2025)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。